Key statistics
As of last trade, Evotec SE (EVTA:FRA) traded at 2.94, 22.50% above the 52 week low of 2.40 set on Dec 19, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 2.94 |
|---|---|
| High | 2.94 |
| Low | 2.94 |
| Bid | 2.96 |
| Offer | 3.10 |
| Previous close | 2.92 |
| Average volume | 12.22 |
|---|---|
| Shares outstanding | 355.76m |
| Free float | 316.06m |
| P/E (TTM) | -- |
| Market cap | 1.31bn USD |
| EPS (TTM) | -0.5334 USD |
Data delayed at least 15 minutes, as of Feb 10 2026 07:04 GMT.
More ▼
Announcements
- EQS-DD: Evotec SE: Dr. Cord Dohrmann, Disposal of 3653 shares (Sell-to-cover)
- EQS-DD: Evotec SE: Dr. Cord Dohrmann, Acquisition of 6760 shares due to vesting (Share Performance Plan 2017)
- EQS-NVR: Evotec SE: Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
- EQS-PVR: Evotec SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
- EQS-PVR: Evotec SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
- EQS-PVR: Evotec SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
- EQS-PVR: Evotec SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
- EQS-PVR: Evotec SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
- EQS-PVR: Evotec SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
- EQS-News: Just – Evotec Biologics Receives Grant for AI-Driven Optimization of Monoclonal Antibody Developability for Affordable Access
More ▼
